Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2017

GlobalData
1007 Pages - GLDATA60409
$2,500.00

Summary

GlobalData's clinical trial report, “Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2017" provides an overview of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) clinical trials scenario. This report provides top line data relating to the clinical trials on Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Companies Mentioned

Novartis AG
Sanofi
Bristol-Myers Squibb Company
Takeda Pharmaceutical Company Ltd
Amgen Inc
Pfizer Inc
Jazz Pharmaceuticals Plc
Celgene Corp
Merck & Co Inc
Juno Therapeutics Inc

'

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 14
Top Five Countries Contributing to Clinical Trials in Central and South America 15
Clinical Trials by G7 Countries: Proportion of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) to Oncology Clinical Trials 16
Clinical Trials by Phase in G7 Countries 18
Clinical Trials in G7 Countries by Trial Status 19
Clinical Trials by E7 Countries: Proportion of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) to Oncology Clinical Trials 21
Clinical Trials by Phase in E7 Countries 22
Clinical Trials in E7 Countries by Trial Status 23
Clinical Trials by Phase 24
In Progress Trials by Phase 25
Clinical Trials by Trial Status 26
Clinical Trials by End Point Status 27
Subjects Recruited Over a Period of Time 28
Clinical Trials by Sponsor Type 29
Prominent Sponsors 30
Top Companies Participating in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials 32
Prominent Drugs 34
Latest Clinical Trials News on Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) 35
Feb 23, 2017: Children’s National Health System Experts Present Data on Novel Approach to Cell Therapy for Cancer Patients 35
Jan 31, 2017: ZIOPHARM Utilizing Non-Viral Sleeping Beauty Platform to Rapidly Produce CAR-Expressing T cells Advancing “Point-of-Care” Approach 35
Jan 09, 2017: Phase I Trial (CALL-1) for C-CAR011 in Adult Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (ALL) in China 36
Dec 22, 2016: Immunomedics Awarded Additional Intellectual Property Protection for IMMU-140, an Antibody-Drug Conjugate With Dual-Therapeutic Potential 36
Dec 19, 2016: Kancera reports positive results for fractalkine blocker KAN0440567 in preclinical models of pain caused by anti-cancer drugs 37
Dec 06, 2016: Juno Therapeutics Presents data on investigational CAR T cell product candidate JCAR017 at 58th American Society of Hematology 37
Dec 06, 2016: Juno Therapeutics Presents data on investigational CAR T cell product candidate JCAR-018 at 58th American Society of Hematology 38
Dec 06, 2016: Affimed Presents New Preclinical Data on AFM-11 at ASH 39
Dec 06, 2016: ARIAD Announces Data Presentations at American Society of Hematology Meeting 39
Dec 04, 2016: Novartis presents results from first global registration trial of CTL019 in pediatric and young adult patients with r/r B-ALL 40
Dec 04, 2016: Kite Pharma Reports 82 Percent of Patients Achieved Complete Remission in Preliminary Analysis from Phase 1 ZUMA-3 and ZUMA-4 Trials of KTE-C19 in Adult and Pediatric Patients with High Burden Relapsed/Refractory Acute Lymphoblastic Leukemia 41
Dec 03, 2016: In Clinical Trials, CAR T Cell Immunotherapy Continues to Yield Complete Responses in Children & Young Adults with Relapsed and Refractory Leukemia 41
Nov 30, 2016: Amgen Announces Presentation Of New Data In Acute Lymphoblastic Leukemia At ASH 2016 42
Nov 29, 2016: Sareum to Present TYK2 Cancer Research Programme at the 2016 AACR-NCI-EORTC International Conference 42
Clinical Trial Profile Snapshots 44
Appendix 1002
Abbreviations 1002
Definitions 1002
Research Methodology 1004
Secondary Research 1005
About GlobalData 1006
Contact Us 1006
Disclaimer 1006
Source 1007

List of Tables
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, Global, Clinical Trials by Region, 2017* 7
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 11
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 12
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, North America, Top Countries, 2017* 13
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2017* 14
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* 15
Proportion of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) to Oncology Clinical Trials, G7 Countries (%), 2017* 17
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 18
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 20
Proportion of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) to Oncology Clinical Trials, E7 Countries (%), 2017* 21
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 22
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 23
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, Global, Clinical Trials by Phase, 2017* 24
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 25
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 26
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 27
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 28
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 29
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 31
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 33
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 34

List of Figures
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, Global, Clinical Trials by Region (%), 2017* 7
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 11
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 12
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 13
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2017* 14
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017* 15
Proportion of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) to Oncology Clinical Trials, G7 Countries (%), 2017* 16
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 18
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 19
Proportion of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) to Oncology Clinical Trials, E7 Countries (%), 2017* 21
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 22
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 23
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, Global, Clinical Trials by Phase (%), 2017* 24
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 25
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 26
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 27
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 28
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 29
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 30
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 32
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 34
GlobalData Methodology 1004

$2,500.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838



Browse All Reports